Poll Results Reveal Readers’ Top Abstracts at SABCS 2025

With the 2025 San Antonio Breast Cancer Symposium kicking off on Tuesday, December 9, in San Antonio, TX, Targeted Oncology is bringing you background on the most exciting abstracts across breast cancer set to be presented.

Targeted Oncology conducted polls on X and LinkedIn to identify which abstracts specialists were most anticipating. See the results of our polls below.

What Are the Top Abstracts to Watch in HR+ Nonmetastatic Breast Cancer at SABCS 2025?

Poll 1: Which of these hormone receptor-positive (HR+) nonmetastic breast cancer abstracts are you most anticipating at SABCS 2025?

The phase 3 lidERA study captured the most votes on X and LinkedIn. The study is investigating the investigational selective estrogen receptor degrader (SERD) vs standard-of-care endocrine therapy for the treatment of patients with estrogen receptor-positive (ER+), HER2-negative (–) early breast cancer.

According to interim data, giredestrant as adjuvant treatment generated significant invasive disease-free survival (IDFS) improvements in ER+, HER2– early-stage breast cancer, outperforming standard of care. Showing a statistically significant and clinically meaningful improvement in IDFS vs standard of care endocrine monotherapy, the trial met its primary end point, becoming the first agent in its class to demonstrate such a superior benefit in the adjuvant setting.

While overall survival (OS) data were immature at the time of the analysis, a positive trend favoring giredestrant was observed. In terms of safety, the agent exhibited a safety profile that was expected and consistent with what was previously established for the agent, with no new safety signals. Full data will be presented at SABCS.

Presentation Details: General Session 1; Wednesday, December 10, at 9:30am CT

What Are the Top Abstracts to Watch in HR+ Metastatic Breast Cancer at SABCS 2025?

Poll 2: Which of these HR+ metastatic breast cancer abstracts are you most anticipating at SABCS 2025?

Primary results from ASCENT-07 were the winner on X and LinkedIn. The study is investigating the TROP2-directed antibody-drug conjugate sacituzumab govitecan (Trodelvy) vs chemotherapy as a first therapy after endocrine therapy in HR+/HER2– metastatic breast cancer. An update announced last month revealed that the study did not meet its primary end point of progression-free survival (PFS).

Presentation Details: General Session 1; Wednesday, December 10, at 9:30am CT

What Are the Top Abstracts to Watch in HER2+ Breast Cancer at SABCS 2025?

Poll 3: Which of these HER2+ breast cancer abstracts are you most anticipating at SABCS 2025?

HER2CLIMB-05 was the top pick on X. The trial is evaluating tucatinib (Tukysa) vs placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab [Herceptin] and pertuzumab [Perjeta]) following chemotherapy-based induction. In October, it was announced that the primary end point of the trial was met, demonstrating a statistically significant improvement in PFS among patients.

Presentation Details: General Session 1; Wednesday, December 10, at 9:30am CT

On LinkedIn, DESTINY-Breast09 was the winner. This presentation will focus on patient-reported outcomes from the study evaluating trastuzumab deruxtecan (T-DXd; Enhertu) plus pertuzumab (Perjeta) vs taxane, trastuzumab, and pertuzumab for first-line HER2+ advanced/metastatic breast cancer.

In October at the ESMO Congress, data revealed a clinically meaningful improvement in PFS regardless of prior treatment, hormone receptor status, or PIK3CA mutations.

Presentation Details: Rapid Fire 6; Wednesday, December 10, at 1:00pm CT

What Are the Top Abstracts to Watch in TNBC at SABCS 2025?

Poll 4: Which of these abstracts in triple-negative breast cancer (TNBC) are you most anticipating at SABCS 2025?

While it was a tie on X, ASCENT-04 took the lead on LinkedIn. The poster presentation will focus on safety outcomes from the study of sacituzumab govitecan plus pembrolizumab (Keytruda) vs chemotherapy and pembrolizumab for previously untreated PD-L1+ metastatic TNBC.

Patient-reported outcome data were reported at the 2025 ESMO Congress and showed the combination may yield maintained quality of life.

Presentation Details: Poster Session 5; Friday, December 12, at 12:30pm ET

What Are the Other Top Breast Cancer Abstracts to Watch at SABCS 2025?

Poll 4: Which of these other breast cancer abstracts are you most anticipating at SABCS 2025?

Results were again split. On X, voters were most excited about ENHANCE, a study assessing the effects of acupuncture vs sham acupuncture and usual care on cancer-related cognitive difficulties among breast cancer survivors. On LinkedIn, the top abstract was looking at menopausal hormone therapy and the risk of breast cancer in patients with a pathogenic BRCA1/2 variant.

Presentation Details: General Session 3; Friday, December 12, at 9:00am CT